Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Status:
Completed
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
Determine how safe and effective lapatinib is when used to treat patients with ErbB2
overexpressing breast cancer that has spread to the brain and is still progressing there even
after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic
radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for
safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during
the course of the study.